메뉴 건너뛰기




Volumn 99, Issue 5, 2014, Pages 469-473

Preventing severe respiratory syncytial virus disease: Passive, active immunisation and new antivirals

Author keywords

[No Author keywords available]

Indexed keywords

MEDI 559; MOTAVIZUMAB; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

EID: 84898544766     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2013-303764     Document Type: Review
Times cited : (29)

References (49)
  • 1
    • 77951653074 scopus 로고    scopus 로고
    • Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: A systematic review and meta-analysis
    • Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545-55.
    • (2010) Lancet , vol.375 , pp. 1545-1555
    • Nair, H.1    Nokes, D.J.2    Gessner, B.D.3
  • 4
    • 0347320558 scopus 로고    scopus 로고
    • The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area
    • DOI 10.1136/adc.88.12.1065
    • Deshpande SA, Northern V. The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child 2003;88:1065-9. (Pubitemid 38064480)
    • (2003) Archives of Disease in Childhood , vol.88 , Issue.12 , pp. 1065-1069
    • Deshpande, S.A.1    Northern, V.2
  • 5
    • 0036677945 scopus 로고    scopus 로고
    • Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998
    • Muller-Pebody B, Edmunds WJ, Zambon MC, et al. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998. Epidemiol Infect 2002;129:99-106.
    • (2002) Epidemiol Infect , vol.129 , pp. 99-106
    • Muller-Pebody, B.1    Edmunds, W.J.2    Zambon, M.C.3
  • 6
    • 0035168864 scopus 로고    scopus 로고
    • Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997
    • DOI 10.1086/317655
    • Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183:16-22. (Pubitemid 32043037)
    • (2001) Journal of Infectious Diseases , vol.183 , Issue.1 , pp. 16-22
    • Shay, D.K.1    Holman, R.C.2    Roosevelt, G.E.3    Clarke, M.J.4    Anderson, L.J.5
  • 7
    • 57149101366 scopus 로고    scopus 로고
    • Management of acute bronchiolitis: Can evidence based guidelines alter clinical practice?
    • Barben J, Kuehni CE, Trachsel D, et al. Management of acute bronchiolitis: can evidence based guidelines alter clinical practice? Thorax 2008;63:1103-9.
    • (2008) Thorax , vol.63 , pp. 1103-1109
    • Barben, J.1    Kuehni, C.E.2    Trachsel, D.3
  • 9
    • 15244341464 scopus 로고    scopus 로고
    • Glucocorticoids for acute viral bronchiolitis in infants and young children
    • Patel H, Platt R, Lozano JM, et al. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database Syst Rev 2004;(3):CD004878.
    • (2004) Cochrane Database Syst Rev , Issue.3
    • Patel, H.1    Platt, R.2    Lozano, J.M.3
  • 10
    • 34848928040 scopus 로고    scopus 로고
    • Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children
    • Ventre K, Randolph AG. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2007;(1):CD000181.
    • (2007) Cochrane Database Syst Rev , Issue.1
    • Ventre, K.1    Randolph, A.G.2
  • 11
    • 37649029306 scopus 로고    scopus 로고
    • Immunoglobulin treatment for respiratory syncytial virus infection
    • Fuller H, Del MC. Immunoglobulin treatment for respiratory syncytial virus infection. Cochrane Database Syst Rev 2006;(4):CD004883.
    • (2006) Cochrane Database Syst Rev , Issue.4
    • Fuller, H.1    Del, M.C.2
  • 12
    • 68049100459 scopus 로고    scopus 로고
    • Report No 91, SIGN accessed Aug 2013
    • Scottish Intercollegiate Guidelines Network (SIGN). Bronchiolitis in children - A national clinical guideline. 2006. Report No 91, SIGN. http://www.sign.ac.uk/pdf/sign91.pdf (accessed Aug 2013).
    • (2006) Bronchiolitis in Children - A National Clinical Guideline
  • 13
    • 80052752406 scopus 로고    scopus 로고
    • A decade of respiratory syncytial virus epidemiology and prophylaxis: Translating evidence into everyday clinical practice
    • Paes BA, Mitchell I, Banerji A, et al. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011;18:e10-19.
    • (2011) Can Respir J , vol.18
    • Paes, B.A.1    Mitchell, I.2    Banerji, A.3
  • 14
    • 79951562634 scopus 로고    scopus 로고
    • Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: A systematic review and additional economic modelling of subgroup analyses
    • Wang D, Bayliss S, Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 2011;15:1-124.
    • (2011) Health Technol Assess , vol.15 , pp. 1-124
    • Wang, D.1    Bayliss, S.2    Meads, C.3
  • 15
    • 0031683919 scopus 로고    scopus 로고
    • Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants
    • The IMpact-RSV Study Group
    • The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102(3 Pt 1):531-7.
    • (1998) Pediatrics , vol.102 , Issue.3 PART 1 , pp. 531-537
  • 16
    • 0242298724 scopus 로고    scopus 로고
    • Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
    • DOI 10.1067/S0022-3476(03)00454-2
    • Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532-40. (Pubitemid 37352516)
    • (2003) Journal of Pediatrics , vol.143 , Issue.4 , pp. 532-540
    • Feltes, T.F.1    Cabalka, A.K.2    Meissner, H.C.3    Piazza, F.M.4    Carlin, D.A.5    Top Jr., F.H.6    Connor, E.M.7    Sondheimer, H.M.8
  • 17
    • 84898542317 scopus 로고    scopus 로고
    • Joint Committee on Vaccination and Immunisation - Respiratory Syncytial Virus (RSV) Subgroup accessed Jul 2013
    • Joint Committee on Vaccination and Immunisation - Respiratory Syncytial Virus (RSV) Subgroup. Minutes of the RSV subgroup on 8th June 2010. 2010. http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/ab/jcvi/dh-094744 (accessed Jul 2013).
    • (2010) Minutes of the RSV Subgroup on 8th June 2010
  • 18
    • 84881346119 scopus 로고    scopus 로고
    • Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children
    • Andabaka T, Nickerson JW, Rojas-Reyes MX, et al. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013;4:CD006602.
    • (2013) Cochrane Database Syst Rev , vol.4
    • Andabaka, T.1    Nickerson, J.W.2    Rojas-Reyes, M.X.3
  • 19
    • 84878537310 scopus 로고    scopus 로고
    • Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against
    • Isaacs D. Should respiratory care in preterm infants include prophylaxis against respiratory syncytial virus? The case against. Paediatr Respir Rev 2013;14:128-9.
    • (2013) Paediatr Respir Rev , vol.14 , pp. 128-129
    • Isaacs, D.1
  • 20
    • 10844278364 scopus 로고    scopus 로고
    • Respiratory syncytial virus prophylaxis - The story so far
    • DOI 10.1053/rmed.2002.1296
    • Simoes EA, Groothuis JR. Respiratory syncytial virus prophylaxis - the story so far. Respir Med 2002;96(Suppl B):S15-24. (Pubitemid 39665386)
    • (2002) Respiratory Medicine , vol.96 , Issue.SUPPL. 2
    • Simoes, E.A.F.1    Groothuis, J.R.2
  • 22
    • 64949096235 scopus 로고    scopus 로고
    • Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: A systematic review and economic evaluation
    • Wang D, Cummins C, Bayliss S, et al. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 2008;12:iii, ix-86.
    • (2008) Health Technol Assess , vol.12
    • Wang, D.1    Cummins, C.2    Bayliss, S.3
  • 23
    • 0037242576 scopus 로고    scopus 로고
    • Current strategies in the prevention of respiratory syncytial virus disease
    • DOI 10.1016/S1526-0542(02)00306-8
    • Paes BA. Current strategies in the prevention of respiratory syncytial virus disease. Paediatr Respir Rev 2003;4:21-7. (Pubitemid 36367581)
    • (2003) Paediatric Respiratory Reviews , vol.4 , Issue.1 , pp. 21-27
    • Paes, B.A.1
  • 24
    • 67649395696 scopus 로고    scopus 로고
    • The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: A Canadian-based analysis
    • Langtot KL, Masoud ST, Paes BA, et al. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Curr Med Res Opin 2008;24:3223-37.
    • (2008) Curr Med Res Opin , vol.24 , pp. 3223-3237
    • Langtot, K.L.1    Masoud, S.T.2    Paes, B.A.3
  • 25
    • 76649093908 scopus 로고    scopus 로고
    • Cost effectiveness of palivizumab in Spain: An analysis using observational data
    • Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11:105-15.
    • (2010) Eur J Health Econ , vol.11 , pp. 105-115
    • Nuijten, M.J.1    Wittenberg, W.2
  • 26
    • 72749117392 scopus 로고    scopus 로고
    • Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands
    • Nuijten MJ, Lebmeier M, Wittenberg W. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands. J Med Econ 2009;12:291-300.
    • (2009) J Med Econ , vol.12 , pp. 291-300
    • Nuijten, M.J.1    Lebmeier, M.2    Wittenberg, W.3
  • 27
    • 71949111112 scopus 로고    scopus 로고
    • The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus
    • Meissner HC, Bocchini JA Jr, Brady MT, et al. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics 2009;124:1676-9.
    • (2009) Pediatrics , vol.124 , pp. 1676-1679
    • Meissner, H.C.1    Bocchini Jr., J.A.2    Brady, M.T.3
  • 28
    • 84882265166 scopus 로고    scopus 로고
    • Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age
    • Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013;132:e341-8.
    • (2013) Pediatrics , vol.132
    • Hall, C.B.1    Weinberg, G.A.2    Blumkin, A.K.3
  • 29
    • 0035927982 scopus 로고    scopus 로고
    • Respiratory syncytial virus and parainfluenza virus
    • DOI 10.1056/NEJM200106213442507
    • Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-28. (Pubitemid 32553362)
    • (2001) New England Journal of Medicine , vol.344 , Issue.25 , pp. 1917-1928
    • Hall, C.B.1
  • 30
    • 84877600733 scopus 로고    scopus 로고
    • Respiratory syncytial virus and recurrent wheeze in healthy preterm infants
    • Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013;368:1791-9.
    • (2013) N Engl J Med , vol.368 , pp. 1791-1799
    • Blanken, M.O.1    Rovers, M.M.2    Molenaar, J.M.3
  • 31
    • 84882764049 scopus 로고    scopus 로고
    • Correspondence: Respiratory syncytial virus and recurrent wheeze
    • Brand PL. Correspondence: respiratory syncytial virus and recurrent wheeze. N Engl J Med 2013;369:782-3.
    • (2013) N Engl J Med , vol.369 , pp. 782-783
    • Brand, P.L.1
  • 32
    • 84870063516 scopus 로고    scopus 로고
    • Benefit and harm from immunity to respiratory syncytial virus: Implications for treatment
    • Habibi MS, Openshaw PJ. Benefit and harm from immunity to respiratory syncytial virus: implications for treatment. Curr Opin Infect Dis 2012;25:687-94.
    • (2012) Curr Opin Infect Dis , vol.25 , pp. 687-694
    • Habibi, M.S.1    Openshaw, P.J.2
  • 33
    • 0003150904 scopus 로고    scopus 로고
    • Potential therapeutic implications of new insights into respiratory syncytial virus disease
    • Openshaw PJ. Potential therapeutic implications of new insights into respiratory syncytial virus disease. Respir Res 2002;3(Suppl 1):S15-20.
    • (2002) Respir Res , vol.3 , Issue.SUPPL. 1
    • Openshaw, P.J.1
  • 34
    • 79953242766 scopus 로고    scopus 로고
    • Hot topics in the prevention of respiratory syncytial virus disease
    • Habibi MS, Patel S, Openshaw P. Hot topics in the prevention of respiratory syncytial virus disease. Expert Rev Vaccines 2011;10:291-3.
    • (2011) Expert Rev Vaccines , vol.10 , pp. 291-293
    • Habibi, M.S.1    Patel, S.2    Openshaw, P.3
  • 35
    • 0014493107 scopus 로고
    • Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine
    • Fulginiti VA, Eller JJ, Sieber OF, et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;89:435-48.
    • (1969) Am J Epidemiol , vol.89 , pp. 435-448
    • Fulginiti, V.A.1    Eller, J.J.2    Sieber, O.F.3
  • 36
    • 0014493282 scopus 로고
    • An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine
    • Kapikian AZ, Mitchell RH, Chanock RM, et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405-21.
    • (1969) Am J Epidemiol , vol.89 , pp. 405-421
    • Kapikian, A.Z.1    Mitchell, R.H.2    Chanock, R.M.3
  • 37
    • 84898546706 scopus 로고    scopus 로고
    • accessed Sep 2013
    • https://www.medimmune.com/ (accessed Sep 2013).
  • 38
    • 84898541095 scopus 로고    scopus 로고
    • accessed Sep 2013
    • http://clinicaltrials.gov/ct2/show/NCT00767416?term=MEDI-559&rank=1 (accessed Sep 2013).
  • 39
    • 84898546826 scopus 로고    scopus 로고
    • accessed Sep 2013
    • http://clinicaltrials.gov/ct2/show/NCT01893554?term= rsv+children+vaccine&rank=2&submit-fld-opt= (accessed Sep 2013).
  • 40
    • 84898539375 scopus 로고    scopus 로고
    • accessed Sep 2013
    • http://clinicaltrials.gov/ct2/show/NCT01459198?term=RSv+children& rank=1 (accessed Sep 2013).
  • 41
    • 84861986082 scopus 로고    scopus 로고
    • Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in the Netherlands
    • Meijboom MJ, Rozenbaum MH, Benedictus A, et al. Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in the Netherlands. Vaccine 2012;30:4691-700.
    • (2012) Vaccine , vol.30 , pp. 4691-4700
    • Meijboom, M.J.1    Rozenbaum, M.H.2    Benedictus, A.3
  • 42
    • 84876871358 scopus 로고    scopus 로고
    • Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein
    • Krzyzaniak MA, Zumstein MT, Gerez JA, et al. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog 2013;9:e1003309.
    • (2013) PLoS Pathog , vol.9
    • Krzyzaniak, M.A.1    Zumstein, M.T.2    Gerez, J.A.3
  • 44
    • 84898543573 scopus 로고    scopus 로고
    • accessed Sep 2013
    • http://clinicaltrials.gov/ct2/show/NCT01797419?term=Safety+Study+of+GS- 5806+to+Treat+Respiratory+Syncytial+Virus&rank=1 (accessed Sep 2013).
  • 45
    • 84898541744 scopus 로고    scopus 로고
    • accessed Aug 2013
    • Alios BioPharma Press Release. http://www.aliosbiopharma.com/news-room/ press-releases/alios-biopharma-initiates-phase-1-clinical-trial-for-rsv- infection (accessed Aug 2013).
    • Alios BioPharma Press Release
  • 46
    • 79960468764 scopus 로고    scopus 로고
    • Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: Prospective cohort study
    • Semple MG, Taylor-Robinson DC, Lane S, et al. Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: prospective cohort study. PLoS ONE 2011;6:e22425.
    • (2011) PLoS ONE , vol.6
    • Semple, M.G.1    Taylor-Robinson, D.C.2    Lane, S.3
  • 47
    • 0026688174 scopus 로고
    • Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus
    • Madge P, Paton JY, McColl JH, et al. Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet 1992;340:1079-83.
    • (1992) Lancet , vol.340 , pp. 1079-1083
    • Madge, P.1    Paton, J.Y.2    McColl, J.H.3
  • 48
    • 0033847164 scopus 로고    scopus 로고
    • Nosocomial respiratory syncytial virus infections: The cost-effectiveness and cost-benefit of infection control
    • Macartney KK, Gorelick MH, Manning ML, et al. Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. Pediatrics 2000;106:520-6. (Pubitemid 30664138)
    • (2000) Pediatrics , vol.106 , Issue.3 , pp. 520-526
    • Macartney, K.K.1    Gorelick, M.H.2    Manning, M.L.3    Hodinka, R.L.4    Bell, L.M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.